Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Heartburn 1

Interventions

Gemcitabine 15Mitomycin 10Docetaxel 7BCG Vaccine 7Cystoscopy 4tislelizumab 3durvalumab 3Radiotherapy 3Epirubicin 3disitamab vedotin 2avelumab 2Hyaluronic Acid 2tremelimumab 1toripalimab 1pemigatinib 1pembrolizumab 1monalizumab 1lornoxicam 1erdafitinib 1enzalutamide 1chondroitin sulfate, sodium hyaluronate drug combination 1bicalutamide 1Watchful Waiting 1VPM1002 recombinant BCG vaccine 1Urine Specimen Collection 1Ty21a typhoid vaccine 1Transurethral Resection of Bladder 1Therapeutics 1Surveys and Questionnaires 1Sugars 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Non-Muscle Invasive Bladder Neoplasms × Ethacrynic Acid × Clear all
NCT02852564 2017-08-22

Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection

University of Kansas Medical Center

Phase 1 Completed
12 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Heartburn, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡